| |
| Target Portfolio >> Proof-of-concept AIRMID Technology |
|
| In Humans: |
- Disease-associated autoreactive T cells are effector-memory T cells with elevated Kv1.3 expression.
- PAP-1 and ShK-186 suppress effector memory T cell- proliferation and cytokine production without impacting naïve and central memory T cells.
|
| In Animals: |
- ShK-186 and PAP-1 ameliorate disease in many models of autoimmune disease
- Multiple sclerosis
- Adoptive experimental autoimmune encephalomyelitis
chronic relapsing-remitting EAE
- Rheumatoid arthritis pristane-induced arthritis
- Type-1 diabetes mellitus
- experimental autoimmune diabetes mellitu
- Contact dermatitis (and psoriasis)
- Acute allergic
- Contact dermatitis
- Other effector memory-mediated T cell
- Responses Delayed type hypersensit
|
| Independent Confirmation: |
Merck: Kv1.3 blockers suppress effector memory T cell-mediated delayed type hypersensitivity in animals. Harvard Dental School: Kv1.3 blocker ameliorated effector memory T cell-mediated experimental bone resorption associated with periodontitis. University of Marseille: Kv1.3 blocker ameliorated effector memory T cell-mediated adoptive experimental autoimmune encephalomyelitis and delayed-type hypersensitivity. |
| |
